On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...

New schizophrenia drug Cobenfy offers hope with fewer side effects targeting symptoms more effectively than traditional ...

Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...

One of the first no-brainer dividend stocks to buy with $100 right now is AT&T. At recent prices, America's second-largest ...

These symptoms disrupt treatment and day-to-day living ... and negative symptoms and improve cognitive issues in some people ...

Bristol-Myers Squibb Company (BMY) shares rose 1.6% after the FDA approved its new drug for schizophrenia. Shares of Cassava Sciences (SAVA) plunged 10.6% after the company reached a $40 million ...

The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of ...

A year of recovery After a challenging period, 2024 has seen a more positive backdrop emerge for the biotechnology sector. In ...